German biopharmaceutical firm Kupando has bolstered its Series A financing with an additional $11 Million, bringing the round's total to $26 million. This capital infusion is earmarked to advance the company's lead candidate, KUP101, into a Phase 1b clinical trial for advanced solid tumors. The funding will also accelerate preclinical programs targeting infectious diseases, marking a pivotal step for its innovative innate immunity platform.
Strong Investor Syndicate Signals Confidence
The investment round was again led by Remiges Ventures and co-led by LifeCare Partners, with new investor Carma Fund joining the syndicate. All existing backers, including Brandenburg Kapital and High-Tech Gründerfonds, also participated, demonstrating robust and widespread confidence in Kupando's direction. This unified support underscores the perceived potential of the company's novel therapeutic approach in a competitive biopharmaceutical landscape.
Investor representatives highlighted the promise of Kupando's science, especially in the current challenging financial climate. Martin Raditsch of Carma Fund noted the platform's potential to deliver impactful solutions for unmet medical needs across different diseases. Kazuhiko Nonomura of Remiges Ventures added that the technology could redefine treatment paradigms in both cancer and infectious diseases.
Advancing a Novel Immunotherapy Candidate
A primary objective for the new funds is to initiate a Phase 1b clinical study of KUP101 in patients with advanced solid tumors. This crucial step will provide the first human data on the drug's safety and efficacy, moving it closer to potential therapeutic use. The trial marks Kupando's significant transition from a preclinical research firm to a clinical-stage biopharmaceutical company.
KUP101 is a differentiated dual Toll-Like Receptor (TLR) 4 and 7 agonist designed to harness the body's innate immune system. Its unique mechanism stimulates a powerful initial immune response while also inducing trained immunity for a sustained, long-term effect. This approach is being developed for the systemic treatment of solid tumors and the prevention and treatment of infectious diseases.
A Vision Rooted in Natural Resilience
Kupando's strategy is centered on the innate immune system, a concept championed by founder and CEO Johanna Holldack. Inspired by the natural resilience of animals, the company aims to leverage this historically undervalued system to create powerful new treatments. Dr. Holldack emphasized that this funding validates the platform's potential and will be instrumental in delivering transformative therapies to patients.
Beyond its primary focus on oncology, Kupando is also applying its technology to combat infectious diseases, including antimicrobial-resistant (AMR) infections. This research arm has garnered support from the German Federal Ministry of Research, Technology and Space, highlighting its national strategic importance. This dual-pronged approach demonstrates the versatility of the company's platform in addressing major global health challenges.
This successful funding round provides Kupando with the critical resources to validate its pioneering immunotherapy approach in a clinical setting. With robust investor backing, the company is poised to advance KUP101 for solid tumors while expanding its promising research into infectious diseases. The upcoming clinical trials will be a key determinant of the platform's potential to reshape treatment by unlocking the power of innate immunity.